Library Subscription: Guest
Journal of Environmental Pathology, Toxicology and Oncology

Published 4 issues per year

ISSN Print: 0731-8898

ISSN Online: 2162-6537

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.4 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.8 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.5 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00049 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.59 SJR: 0.429 SNIP: 0.507 CiteScore™:: 3.9 H-Index: 49

Indexed in

T3 Promotes Glioma Cell Senescence and Apoptosis via THRA and THRB

Volume 40, Issue 4, 2021, pp. 1-9
DOI: 10.1615/JEnvironPatholToxicolOncol.2021038740
Get accessDownload

ABSTRACT

Glioma is one of the most common types of primary intracranial tumors. The relationship between triiodothyronine (T3) and glioma is not clear. This study aimed to investigate the effect of T3 on the proliferation of glioma cells and its mechanism. Cell viability was analyzed by cell counting kit 8 assay. Flow cytometry analysis was used to detect cell apoptosis and cell cycle. Thyroid hormone receptor α (THRA) and thyroid hormone receptor β (THRB) were silenced by transfecting si-THRA and si-THRB plasmids into HS683 and A172 glioma cells. Western blot was performed to assess the protein expressions. The results indicated that triiodothyronine (T3) affected the viability, apoptosis and cell cycle of HS683 and A172 glioma cells. Cell apoptosis was significantly inhibited in si-THRA and si-THRB experimental groups. Moreover, knockdown of THRA and THRB reversed the G1 and G2 phase arrest led by T3 and induced an up-regulation of cyclin D1 expression. The phosphorylated extracellular signal-regulated kinase (p-ERK), p-AKT, and phosphorylated signal transducer and activator of transcription (p-STAT3) proteins were markedly increased by inhibiting THRA and THRB in HS683 and A172 glioma cells. T3 affected apoptosis and cell cycle of glioma cells through regulating THRA and THRB expressions. THRA and THRB may affect glioma development through regulating, at least partially, the mitogen-activated protein kinase (MAPK)/ERK and phosphoinositide 3-kinase (PI3K)/Akt signaling pathways.

REFERENCES
  1. Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma subclassifications and their clinical significance. Neurotherapeutics. 2017;14(2):284-97.

  2. Zhang L, Zhang F, Li Y, Qi X, Guo Y. Triiodothyronine promotes cell proliferation of breast cancer via modulating miR-204/amphiregulin. Pathol Oncol Res. 2019;25(2):653-8.

  3. Ovcaricek PP, Frobe A, Verburg FA, Murgic J, Butkovic MB, Ovcaricek S, Mazuran B, Kruslin B, Jakovcevic D, Soipi S, Ruzic B, Milosevic M, Krilic D, Franceschi M, Jukic T. Association of triiodothyronine levels with prostate cancer histopathological differentiation and tumor stage. Anticancer Res. 2020;40(4):2323-9.

  4. Latteyer S, Christoph S, Theurer S, Hones GS, Schmid KW, Fuhrer D, Moeller LC. Thyroxine promotes lung cancer growth in an orthotopic mouse model. Endocr Relat Cancer. 2019;26(6):565-74.

  5. Shinderman-Maman E, Cohen K, Weingarten C, Nabriski D, Twito O, Baraf L, Hercbergs A, Davis PJ, Werner H, Ellis M, Ashur-Fabian O. The thyroid hormone-alphavbeta3 integrin axis in ovarian cancer: Regulation of gene transcription and MAPK-dependent proliferation. Oncogene. 2016;35(15):1977-87.

  6. Sarosiek K, Gandhi AV, Saxena S, Kang CY, Chipitsyna GI, Yeo CJ, Arafat HA. Hypothyroidism in pancreatic cancer: Role of exogenous thyroid hormone in tumor invasion-preliminary observations. J Thyroid Res. 2016;2016:2454989.

  7. Fee YS, Chin YT, Yang YSH, Wei PL, Wu HC, Shih A, Lu YT, Pedersen JZ, Incerpi S, Liu LF, Lin HY, Davis PJ. The combination of tetraiodothyroacetic acid and cetuximab inhibits cell proliferation in colorectal cancers with different K-ras status. Steroids. 2016;111:63-70.

  8. Lin HY, Sun M, Tang HY, Lin C, Luidens MK, Mousa SA, Incerpi S, Drusano GL, Davis FB, Davis PJ. L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: Activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol. 2009;296(5):C980-91.

  9. Goemann IM, Marczyk VR, Recamonde-Mendoza M, Wajner SM, Graudenz MS, Maia AL. Decreased expression of the thyroid hormone-inactivating enzyme type 3 deiodinase is associated with lower survival rates in breast cancer. Sci Rep. 2020;10(1):13914.

  10. Krashin E, Piekielko-Witkowska A, Ellis M, Ashur-Fabian O. Thyroid hormones and cancer: A comprehensive review of preclinical and clinical studies. Front Endocrinol. 2019;10:59.

  11. Delgado-Gonzalez E, Sanchez-Tusie AA, Morales G, Aceves C, Anguiano B. Triiodothyronine attenuates prostate cancer progression mediated by beta-adrenergic stimulation. Mol Med. 2016;22:1-11.

  12. Kotolloshi R, Mirzakhani K, Ahlburg J, Kraft F, Pungsrinont T, Baniahmad A. Thyroid hormone induces cellular senescence in prostate cancer cells through induction of DEC1. J Steroid Biochem Mol Biol. 2020;201:105689.

  13. Shinderman-Maman E, Weingarten C, Moskovich D, Werner H, Hercbergs A, Davis PJ, Ellis M, Ashur-Fabian O. Molecular insights into the transcriptional regulatory role of thyroid hormones in ovarian cancer. Mol Carcinog. 2018;57(1):97-105.

  14. Moriggi G, Verga Falzacappa C, Mangialardo C, Michienzi S, Stigliano A, Brunetti E, Toscano V, Misiti S. Thyroid hormones (T3 and T4): Dual effect on human cancer cell proliferation. Anticancer Res. 2011;31(1):89-96.

  15. Michienzi S, Bucci B, Verga Falzacappa C, Patriarca V, Stigliano A, Panacchia L, Brunetti E, Toscano V, Misiti S. 3,3',5-Triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy. J Endocrinol. 2007;193(2):209-23.

  16. Dentice M, Luongo C, Ambrosio R, Sibilio A, Casillo A, Iaccarino A, Troncone G, Fenzi G, Larsen PR, Salvatore D. Beta-catenin regulates deiodinase levels and thyroid hormone signaling in colon cancer cells. Gastroenterology. 2012;143(4):1037-47.

  17. Davis FB, Tang HY, Shih A, Keating T, Lansing L, Hercbergs A, Fenstermaker RA, Mousa A, Mousa SA, Davis PJ, Lin HY. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res. 2006;66(14):7270-5.

  18. Lin HY, Tang HY, Keating T, Wu YH, Shih A, Hammond D, Sun M, Hercbergs A, Davis FB, Davis PJ. Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: Both actions are integrin and ERK mediated. Carcinogenesis. 2008;29(1):62-9.

  19. Liappas A, Mourouzis I, Zisakis A, Economou K, Lea RW, Pantos C. Cell-type-dependent thyroid hormone effects on glioma tumor cell lines. J Thyroid Res. 2011;2011:856050.

  20. Bunevicius A, Deltuva VP, Tamasauskas S, Smith T, Laws ER, Bunevicius R, Iervasi G, Tamasauskas A. Preoperative low tri-iodothyronine concentration is associated with worse health status and shorter five year survival of primary brain tumor patients. Oncotarget. 2017;8(5):8648-56.

  21. Ortiga-Carvalho TM, Sidhaye AR, Wondisford FE. Thyroid hormone receptors and resistance to thyroid hormone disorders. Nat Rev Endocrinol. 2014;10(10):582-91.

  22. Liu YY, Brent GA. Thyroid hormone and the brain: Mechanisms of action in development and role in protection and promotion of recovery after brain injury. Pharmacol Ther. 2018;186:176-85.

  23. Bernal J. Thyroid hormone receptors in brain development and function. Nat Clin Pract Endocrinol Metab. 2007;3(3):249-59.

  24. Idrees T, Price JD, Piccariello T, Bianco AC. Sustained release T3 therapy: Animal models and translational applications. Front Endocrinol. 2019;10:544.

  25. Matheson CJ, Backos DS, Reigan P. Targeting WEE1 kinase in cancer. Trends Pharmacol Sci. 2016;37(10):872-81.

  26. Song D, Liang H, Qu B, Li Y, Liu J, Chen C, Zhang D, Zhang X, Gao A. Moxidectin inhibits glioma cell viability by inducing G0/G1 cell cycle arrest and apoptosis. Oncol Rep. 2018;40(3):1348-58.

  27. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev. 2010;31(2):139-70.

  28. Garcia-Silva S, Aranda A. The thyroid hormone receptor is a suppressor of rasmediated transcription, proliferation, and transformation. Mol Cell Biol. 2004;24(17):7514-23.

  29. Zhu XG, Zhao L, Willingham MC, Cheng SY. Thyroid hormone receptors are tumor suppressors in a mouse model of metastatic follicular thyroid carcinoma. Oncogene. 2010;29(13):1909-19.

  30. Horkko TT, Tuppurainen K, George SM, Jernvall P, Karttunen TJ, Makinen MJ. Thyroid hormone receptor beta1 in normal colon and colorectal cancer-association with differentiation, polypoid growth type and K-ras mutations. Int J Cancer. 2006;118(7):1653-9.

  31. Hwang SL, Lin CL, Lieu AS, Hwang YF, Howng SL, Hong YR, Chang DS, Lee KS. The expression of thyroid hormone receptor isoforms in human astrocytomas. Surg Neurol. 2008;70(Suppl 1):S1:4-8; discussion S1:8.

  32. Nauman P. Thyroid hormones in the central nervous system (CNS) and their effect on neoplasm formation, particularly on the development and course of glioblastoma multiforme - research hypothesis. Endokrynol Pol. 2015;66(5):444-59.

  33. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, Varambally S. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649-58.

  34. Park JW, Zhao L, Willingham M, Cheng SY. Oncogenic mutations of thyroid hormone receptor beta. Oncotarget. 2015;6(10):8115-31.

  35. Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside. Semin Cancer Biol. 2019;59:125-32.

  36. Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20(2):74-88.

  37. Kurtzeborn K, Kwon HN, Kuure S. MAPK/ERK signaling in regulation of renal differentiation. Int J Mol Sci. 2019;20(7):1779.

  38. Safa A, Abak A, Shoorei H, Taheri M, Ghafouri-Fard S. MicroRNAs as regulators of ERK/MAPK pathway: A comprehensive review. Biomed Pharmacother. 2020;132: 110853.

  39. Jin T, Li D, Yang T, Liu F, Kong J, Zhou Y. PTPN1 promotes the progression of glioma by activating the MAPK/ERK and PI3K/AKT pathways and is associated with poor patient survival. Oncol Rep. 2019;42(2):717-25.

  40. Perreault S, Larouche V, Tabori U, Hawkin C, Lippe S, Ellezam B, Decarie JC, Theoret Y, Metras ME, Sultan S, Cantin E, Routhier ME, Caru M, Legault G, Bouffet E, Lafay-Cousin L, Hukin J, Erker C, Jabado N. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. Bmc Cancer. 2019;19(1):1250.

  41. Li B, Wang F, Liu N, Shen W, Huang T. Astragaloside IV inhibits progression of glioma via blocking MAPK/ERK signaling pathway. Biochem Biophys Res Commun. 2017;491(1):98-103.

  42. Xi X, Liu N, Wang Q, Chu Y, Yin Z, Ding Y, Lu Y. ACT001, a novel PAI-1 inhibitor, exerts synergistic effects in combination with cisplatin by inhibiting PI3K/AKT pathway in glioma. Cell Death Dis. 2019;10(10):757.

CITED BY
  1. Tan Yuwei , Liu Liang , Zhang Xuemei , Xue Yu , Gao Jiafu , Zhao Jintao , Chi Nannan , Zhu Yanli, THUMPD3-AS1 Is Correlated with Gastric Cancer and Regulates Cell Function through miR-1252-3p and CXCL17 , Critical Reviews in Eukaryotic Gene Expression, 32, 8, 2022. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain